Good morning, everyone, and how are you today? We are doing just fine, thank you, despite the soggy skies overhead. After all, as the Morning Mayor used to say: “Every new day should be unwrapped like a precious gift.” So while you tug on the ribbon, we will brew another cup of stimulation — chocolate raspberry is our choice — and continue foraging for items of interest. Speaking of which, here is the latest selection. Meanwhile, we hope you have a smashing day and achieve all your goals. One small note, we will back on Thursday as we sequester tomorrow to observe ancient rituals. A colleague will be here in our stead. Ta-ta!
The U.S. Supreme Court asked the Biden administration for an opinion on whether it should hear a challenge by Teva Pharmaceuticals to a $235 million award to GlaxoSmithKline in a patent dispute over generic heart medication, Reuters notes. Teva appealed a lower court ruling that reinstated the jury award for GSK. The case could affect the future of so-called “skinny labels,” which allow generic drugmakers to avoid patent lawsuits if a generic drug label omits potentially infringing uses of a brand-name drug. Teva has argued that it followed U.S. Food and Drug Administration instructions to “carve out” from its label a patented method for using the drug to treat heart failure.
The U.S. Supreme Court declined to hear a bid by Biogen to win reinstatement of a patent on its blockbuster multiple sclerosis drug in a dispute with Mylan Pharmaceuticals, Reuters writes. The court turned away an appeal of a lower court decision to invalidate the Biogen patent in a ruling that helped clear the way for Mylan to produce a generic version of the drug, Tecfidera. Biogen sued Mylan, now part of Viatris, claiming patent infringement, but U.S. District Judge Irene Keeley ruled in 2020 that a key Tecfidera patent was invalid. Mylan launched its generic that August. Tecfidera is still a best-selling drug for Biogen, but its sales have dropped due to generic competition.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect